0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Corbus Pharmaceuticals Holding

Healthcare US CRBP

33.5USD
-2.04(5.74%)

Last update at 2024-04-25T20:00:00Z

Day Range

32.0335.09
LowHigh

52 Week Range

2.1113.17
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -42.34690M -45.64043M -111.26938M -71.45372M -55.67214M
Minority interest - - - - -
Net income -55.83319M -45.55259M -111.30443M -69.15491M -55.67214M
Selling general administrative 18.70M 20.43M 28.48M 23.64M 12.96M
Selling and marketing expenses - - - - -
Gross profit - 0.88M 3.94M 36.14M 4.82M
Reconciled depreciation 1.49M 1.64M 1.69M 1.23M 0.49M
Ebit -39.83544M -55.98902M -122.81023M -77.10458M -57.33444M
Ebitda -29.50485M -56.26812M -122.10923M -76.94596M -56.84050M
Depreciation and amortization 10.33M -0.27909M 0.70M 0.16M 0.49M
Non operating income net other - - 12.57M 5.65M 0.09M
Operating income -39.83544M -55.98902M -122.81023M -77.10458M -56.74771M
Other operating expenses 34.84M 56.87M 126.75M 113.25M 61.57M
Interest expense 2.13M 1830.49M 1.03M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - 1.23M 0.98M
Net interest income -2.13209M -1.83049M -1.02836M 1.23M 0.98M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 13.49M -0.08784M 0.04M -2.29881M 1.08M
Total revenue 0.00000M 0.88M 3.94M 36.14M 4.82M
Total operating expenses 34.84M 56.87M 126.75M 113.25M 61.57M
Cost of revenue - - - 89.60M 48.61M
Total other income expense net -2.51146M 10.35M 11.54M 5.65M 0.09M
Discontinued operations - - - - -
Net income from continuing ops -42.34690M -45.64043M -111.26938M -71.45372M -55.67214M
Net income applicable to common shares -42.34690M -45.64043M -111.26938M -71.45372M -55.67214M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 66.31M 107.73M 102.29M 49.14M 46.99M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.79M 2.37M 3.71M 6.41M 2.49M
Total liab 33.32M 38.62M 57.02M 42.98M 19.47M
Total stockholder equity 32.99M 69.11M 45.27M 6.16M 27.52M
Deferred long term liab - - - - 1.38M
Other current liab 6.04M 0.13M 0.80M 22.45M 9.89M
Common stock 0.00042M 0.01M 0.00988M 0.00647M 0.00573M
Capital stock 0.00042M 0.01M 0.00988M 0.00647M 0.00573M
Retained earnings -392.08067M -349.73376M -304.09334M -192.82396M -121.37024M
Other liab 0.02M 0.02M - - 1.38M
Good will - - - - -
Other assets 0.63M 0.52M 6.15M 0.08M 0.04M
Cash 17.00M 25.01M 85.43M 31.75M 41.75M
Cash and equivalents - - - - -
Total current liabilities 12.64M 17.01M 31.90M 34.89M 18.09M
Current deferred revenue - 10.09M 22.01M - 1.46M
Net debt 8.09M 1.58M -58.59705M -22.30305M -41.35416M
Short term debt 4.43M 5.00M 1.71M 1.35M 0.39M
Short long term debt 3.15M 3.86M 0.71M 0.75M 0.39M
Short long term debt total 25.09M 26.59M 26.84M 9.45M 0.39M
Other stockholder equity 425.20M 418.89M 349.36M 198.98M 149.56M
Property plant equipment 5.50M 7.00M 9.32M 5.08M 2.71M
Total current assets 60.18M 100.20M 92.07M 38.15M 44.24M
Long term investments - - - - -
Net tangible assets 32.99M 69.11M 45.27M 6.16M 27.52M
Short term investments 42.19M 72.64M - - -
Net receivables - - 2.58M 2.68M -
Long term debt 15.98M 15.64M 18.03M - -
Inventory - - 0.35M -2.68106M -
Accounts payable 2.17M 1.78M 7.38M 11.09M 6.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.12609M -0.06245M - -1.40596M -0.66658M
Additional paid in capital - - - - -
Common stock total equity - - 0.00988M 0.00647M 0.00573M
Preferred stock total equity - - - - -
Retained earnings total equity - - -304.09334M -192.82396M -121.37024M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.63M 0.52M 0.90M 0.08M 0.04M
Deferred long term asset charges - - - - -
Non current assets total 6.13M 7.53M 10.22M 10.99M 2.75M
Capital lease obligations 5.96M 7.09M 8.10M 8.69M -
Long term debt total - - 18.03M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 30.07M -73.38625M -0.48449M -2.74254M -2.30042M
Change to liabilities -0.25683M -5.95630M -3.46892M 10.46M 9.02M
Total cashflows from investing activities 30.07M -73.41652M -0.48449M -2.74254M -2.30042M
Net borrowings -0.53361M 0.06M 18.71M -3.17709M -0.63299M
Total cash from financing activities -0.53361M 60.82M 154.87M 38.46M 11.42M
Change to operating activities -3.76668M -11.35847M -0.79877M 12.25M 5.39M
Net income -42.34690M -45.64043M -111.26938M -71.45372M -55.67214M
Change in cash -8.00392M -60.77681M 54.70M -9.99978M -20.94802M
Begin period cash flow 25.68M 86.45M 31.75M 41.75M 62.70M
End period cash flow 17.67M 25.68M 86.45M 31.75M 41.75M
Total cash from operating activities -37.54444M -48.18370M -99.68570M -45.72073M -30.06725M
Issuance of capital stock 0.00000M 62.59M 142.20M 40.68M 12.05M
Depreciation 1.49M 1.64M 1.69M 1.23M 0.49M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - 9.57M 5.39M
Change to account receivables - 1.62M 0.96M 5.00M 12.50M
Sale purchase of stock - - 142.20M 40.68M 12.05M
Other cashflows from financing activities 1.83M -0.83606M 13.63M -1.60804M -0.19855M
Change to netincome 6.60M 10.81M 12.80M 12.03M 7.68M
Capital expenditures 0.01M 0.05M 0.48M 2.74M 2.30M
Change receivables - - - 5.00M 12.50M
Cash flows other operating - - 1.33M 0.19M -4.08658M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 54.70M -9.99978M -20.94802M
Change in working capital -4.02351M -15.69647M -3.20492M 12.48M 17.01M
Stock based compensation 5.72M 9.48M 12.46M 11.98M 7.61M
Other non cash items 1.62M 0.95M 0.29M 0.05M 0.42M
Free cash flow -37.55788M -48.23787M -100.17019M -48.46327M -32.36767M

Fundamentals

  • Previous Close 35.54
  • Market Cap24.33M
  • Volume142325
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-45.09336M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -16.13683M
  • Diluted EPS TTM-11.12

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRBP
Corbus Pharmaceuticals Holding		 -2.04 5.74% 33.50 - - 163.32 73.96 8.26 -0.4528
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Corbus Pharmaceuticals Holding

500 River Ridge Drive, Norwood, MA, United States, 02062

Key Executives

Name Title Year Born
Dr. Yuval Cohen Ph.D. CEO & Director 1975
Mr. Sean F. Moran CPA, M.B.A., CPA, MBA Chief Financial Officer 1958
Mr. Craig Stuart Millian M.B.A. Chief Operating Officer 1969
Dr. Rachael Brake Ph.D. Chief Scientific Officer 1972
Ted Jenkins Sr. Director of Investor Relations & Corp. Communications NA
Ms. Lindsey Smith Head of Corp. Communications & Patient Advocacy NA
Ms. Christina Bertsch Head of HR NA
Scott Constantine Sr. Director & Head of Clinical Operations NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).